Page last updated: 2024-12-11
retinamide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
retinamide: metabolite of tretinoin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5370221 |
| SCHEMBL ID | 60864 |
| MeSH ID | M0153729 |
Synonyms (22)
| Synonym |
|---|
| ro 4-3930 |
| retinoyl amid |
| all-trans-retinamide |
| vitamin a amide |
| vitamin a-saeureamid [german] |
| retinamide |
| retinamide, all-trans- |
| retinoyl amide |
| all-trans-vitamin a amide |
| (2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide |
| 20638-84-0 |
| bqc43t81dz , |
| vitamin a-saeureamid |
| unii-bqc43t81dz |
| vitamin a amide, all-trans |
| SCHEMBL60864 |
| 15-aminoretinal # |
| 3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide |
| J-013485 |
| Q27274815 |
| DTXSID001318373 |
| (2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide |
Research Excerpts
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Retinamide treatment resulted in increased ratios of deamidated verses transamidated levels of Bcl-xL in U87 cells." | ( Retinamide-induced apoptosis in glioblastomas is associated with down-regulation of Bcl-xL and Bcl-2 proteins. Higashikubo, R; Jiang, Z; Lytle, RA; Rich, KM; Zheng, X, 2005) | 2.49 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " The results of cytotoxicity and flow cytometry data showed that the compounds had a moderate to strong effect against MCF-7 and HepG2 cells and were less toxic to HEK293 cells." | ( Novel all trans-retinoic Acid derivatives: cytotoxicity, inhibition of cell cycle progression and induction of apoptosis in human cancer cell lines. Al-Khedhairy, AA; Al-Oqail, MM; Al-Sheddi, ES; Farshori, NN; Musarrat, J; Saquib, Q; Siddiqui, MA, 2015) | 0.42 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " This method was applied to determine the pharmacokinetic parameters." | ( Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. Cao, L; Di, B; Ding, L; Hang, TJ; Liu, WY; Ma, PC; Sun, D; Wang, Y; Yang, Q; Yu, P; Zheng, F, 2008) | 0.35 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Group A received oral retinamide at a dosage of 20mg/kg, every day for eight weeks." | ( [Treatment of oral leukoplakia with retinamide]. Liu, X; Shen, S; Sun, Z, 1996) | 0.88 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (41)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (9.76) | 18.7374 |
| 1990's | 12 (29.27) | 18.2507 |
| 2000's | 14 (34.15) | 29.6817 |
| 2010's | 9 (21.95) | 24.3611 |
| 2020's | 2 (4.88) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 21.48
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.48) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 11 (26.19%) | 5.53% |
| Reviews | 1 (2.38%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 30 (71.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Clinical Trials (6)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) Retinamide, 4-HPR) Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL) [NCT02495415] | Phase 2 | 140 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| "A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children With Recurrent or Resistant Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), and Non-Hodgkin's Lymphoma (NHL) IND #70,058" [NCT01187810] | Phase 1 | 3 participants (Actual) | Interventional | 2010-08-31 | Terminated(stopped due to drug supply) | ||
| A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion [NCT04234048] | Phase 1 | 46 participants (Anticipated) | Interventional | 2023-12-18 | Recruiting | ||
| Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma [NCT01535157] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2012-02-29 | Terminated(stopped due to drug combination not providing any efficacy. Will use this data in opening new trial) | ||
| A Single Arm, Phase II Study to Determine the Safety and Efficacy of 4-HPRN-(4-Hydroxyphenyl) Retinamide for Treating Oral Intraepithelial Neoplasia [NCT00003223] | Phase 2 | 5 participants (Actual) | Interventional | 1997-12-31 | Terminated(stopped due to Closed due to poor accrual.) | ||
| Phase II Clinical Trial of N-(4-hydroxyphenyl) Retinamide (4-HPR) and Tamoxifen in Breast Neoplasia, Administration During the Period Between the Diagnostic Core Biopsy and Definitive Surgery [NCT00003099] | Phase 2 | 52 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||